BDBM330808 (S)-2-(5-((1-((4-fluorophenyl)sulfonyl)-6-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-1,2,3,4-tetrahydroquinolin-2-yl)methyl)-1,3,4-oxadiazol-2-yl)-N,N-dimethylacetamide::US9725443, 21

SMILES CN(C)C(=O)Cc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1

InChI Key InChIKey=BZJZPVQQQMJXRF-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 330808   

TargetNuclear receptor ROR-gamma(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330808((S)-2-(5-((1-((4-fluorophenyl)sulfonyl)-6-(1,1,1,3...)
Affinity DataIC50: 93nMAssay Description:The binding of potential ligands to RORγ is measured by competition with [3H] 25-hydroxycholesterol using a scintillation proximity assay (SPA) ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/12/2019
Entry Details
US Patent